Ann Pediatr Endocrinol Metab.  2017 Jun;22(2):82-89. 10.6065/apem.2017.22.2.82.

Metabolic syndrome induced by anticancer treatment in childhood cancer survivors

• Chueh HW
• Yoo JH

• KMID: 2383901
• DOI: http://doi.org/10.6065/apem.2017.22.2.82

Abstract

The number of childhood cancer survivors is increasing as survival rates improve. However, complications after treatment have not received much attention, particularly metabolic syndrome. Metabolic syndrome comprises central obesity, dyslipidemia, hypertension, and insulin resistance, and cancer survivors have higher risks of cardiovascular events compared with the general population. The mechanism by which cancer treatment induces metabolic syndrome is unclear. However, its pathophysiology can be categorized based on the cancer treatment type administered. Brain surgery or radiotherapy may induce metabolic syndrome by damaging the hypothalamic-pituitary axis, which may induce pituitary hormone deficiencies. Local therapy administered to particular endocrine organs directly damages the organs and causes hormone deficiencies, which induce obesity and dyslipidemia leading to metabolic syndrome. Chemotherapeutic agents interfere with cell generation and growth, damage the vascular endothelial cells, and increase the cardiovascular risk. Moreover, chemotherapeutic agents induce oxidative stress, which also induces metabolic syndrome. Physical inactivity caused by cancer treatment or the cancer itself, dietary restrictions, and the frequent use of antibiotics may also be risk factors for metabolic syndrome. Since childhood cancer survivors with metabolic syndrome have higher risks of cardiovascular events at an earlier age, early interventions should be considered. The optimal timing of interventions and drug use has not been established, but lifestyle modifications and exercise interventions that begin during cancer treatment might be beneficial and tailored education and interventions that account for individual patients' circumstances are needed. This review evaluates the recent literature that describes metabolic syndrome in cancer survivors, with a focus on its pathophysiology.

Keyword

Neoplasms; Antineoplastic protocols; Survivors; Metabolic syndrome X; Life style

MeSH Terms

Anti-Bacterial Agents
Antineoplastic Protocols
Brain
Dyslipidemias
Early Intervention (Education)
Education
Endothelial Cells
Humans
Hypertension
Insulin Resistance
Life Style
Metabolic Syndrome X
Obesity
Obesity, Abdominal
Oxidative Stress
Radiotherapy
Risk Factors
Survival Rate
Survivors*
Anti-Bacterial Agents

Reference

1. Park HJ, Moon EK, Yoon JY, Oh CM, Jung KW, Park BK, et al. Incidence and survival of childhood cancer in Korea. Cancer Res Treat. 2016; 48:869–882. PMID: 26790965.

2. de Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010; 11:193–203. PMID: 20152771.

3. Talvensaari KK, Lanning M, Tapanainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996; 81:3051–3055. PMID: 8768873.

4. Casco S, Soto-Vega E. Development of metabolic syndrome associated to cancer therapy: review. Horm Cancer. 2016; 7:289–295. PMID: 27704369.

5. Gibson TM, Ehrhardt MJ, Ness KK. Obesity and metabolic syndrome among adult survivors of childhood leukemia. Curr Treat Options Oncol. 2016; 17:17. PMID: 26951206.

6. Lim HH, Kang MJ, Yun IS, Lee YA, Shin CH, Yang SW. Prevalence and risk factors of the metabolic syndrome in young adults with childhood-onset hypopituitary growth hormone deficiency. Korean J Pediatr. 2010; 53:892–897. PMID: 21189960.

7. Sohn YB, Kim SJ, Park SW, Kim SH, Cho SY, Lee SH, et al. The metabolic syndrome and body composition in childhood cancer survivors. Korean J Pediatr. 2011; 54:253–259. PMID: 21949520.

8. Bang KW, Seo SY, Lee JW, Jang PS, Jung MH, Chung NG, et al. Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia. Korean J Pediatr. 2012; 55:121–127. PMID: 22574072.

9. Shin H, Choi YJ, Lee YH, Shin JH, Yang S. Prevalence of the components of metabolic syndrome in childhood cancer survivors. Clin Pediatr Hematol Oncol. 2014; 21:23–28.

10. Odame I, Reilly JJ, Gibson BE, Donaldson MD. Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1994; 71:147–149. PMID: 7944537.

11. Didi M, Didcock E, Davies HA, Ogilvy-Stuart AL, Wales JK, Shalet SM. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr. 1995; 127:63–67. PMID: 7608813.

12. Neville KA, Cohn RJ, Steinbeck KS, Johnston K, Walker JL. Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab. 2006; 91:4401–4407. PMID: 16954158.

13. Malhotra J, Tonorezos ES, Rozenberg M, Vega GL, Sklar CA, Chou J, et al. Atherogenic low density lipoprotein phenotype in long-term survivors of childhood acute lymphoblastic leukemia. J Lipid Res. 2012; 53:2747–2754. PMID: 22984143.

14. Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol. 2014; 165:364–374. PMID: 24467690.

15. Rosen GP, Nguyen HT, Shaibi GQ. Metabolic syndrome in pediatric cancer survivors: a mechanistic review. Pediatr Blood Cancer. 2013; 60:1922–1928. PMID: 23913590.

16. Barbosa-Cortés L, López-Alarcón M, Mejía-Aranguré JM, Klünder-Klünder M, Del Carmen Rodríguez-Zepeda M, Rivera-Márquez H, et al. Adipokines, insulin resistance, and adiposity as a predictors of metabolic syndrome in child survivors of lymphoma and acute lymphoblastic leukemia of a developing country. BMC Cancer. 2017; 17:125. PMID: 28193268.

17. Morel S, Leahy J, Fournier M, Lamarche B, Garofalo C, Grimard G, et al. Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. J Lipid Res. 2017; 58:982–993. PMID: 28274961.

18. Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012; 120:4505–4512. PMID: 23034279.

19. Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2004; 22:3558–3562. PMID: 15337805.

20. Wilson CL, Liu W, Yang JJ, Kang G, Ojha RP, Neale GA, et al. Genetic and clinical factors associated with obesity among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort. Cancer. 2015; 121:2262–2270. PMID: 25963547.

21. Marcoux S, Drouin S, Laverdière C, Alos N, Andelfinger GU, Bertout L, et al. The PETALE study: Late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors. Pediatr Blood Cancer. 2017; 64. PMID: 27555087.

22. Kate A, Kadambari D. Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy. J Pharmacol Pharmacother. 2016; 7:28–30. PMID: 27127393.

23. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary. 2009; 12:40–50. PMID: 18270844.

24. Westerink NL, Nuver J, Lefrandt JD, Vrieling AH, Gietema JA, Walenkamp AM. Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Crit Rev Oncol Hematol. 2016; 108:128–136. PMID: 27931830.

25. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000; 18:1725–1732. PMID: 10764433.

26. Sheean P, Liang H, Schiffer L, Arroyo C, Stolley M. Examining the prevalence of metabolic syndrome among overweight/obese African-American breast cancer survivors vs. matched non-cancer controls. J Cancer Surviv. 2017; 11:102–110. PMID: 27562474.

27. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab. 2007; 92:491–496. PMID: 17090642.

28. Tell R, Lundell G, Nilsson B, Sjödin H, Lewin F, Lewensohn R. Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004; 60:395–400. PMID: 15380571.

29. Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, Storb RF, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood. 2009; 113:306–308. PMID: 18838614.

30. Mohapatra S, Bansal D, Bhalla AK, Verma Attri S, Sachdeva N, Trehan A, et al. Is there an increased risk of metabolic syndrome among childhood acute lymphoblastic leukemia survivors? A developing country experience. Pediatr Hematol Oncol. 2016; 33:136–149. PMID: 26984439.

31. Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009; 27:2374–2381. PMID: 19364956.

32. Mayer EI, Reuter M, Dopfer RE, Ranke MB. Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood. Horm Res. 2000; 53:193–199. PMID: 11044803.

33. Brennan BM, Rahim A, Blum WF, Adams JA, Eden OB, Shalet SM. Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxf). 1999; 50:163–169. PMID: 10396357.

34. Ness KK, Hudson MM, Ginsberg JP, Nagarajan R, Kaste SC, Marina N, et al. Physical performance limitations in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27:2382–2389. PMID: 19332713.

35. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–2752. PMID: 16157765.

36. Rugbjerg K, Mellemkjaer L, Boice JD, Køber L, Ewertz M, Olsen JH. Cardiovascular disease in survivors of adolescent and young adult cancer: a Danish cohort study, 1943-2009. J Natl Cancer Inst. 2014; 106:dju110. PMID: 24848622.

37. Bao PP, Zheng Y, Nechuta S, Gu K, Cai H, Peng P, et al. Exercise after diagnosis and metabolic syndrome among breast cancer survivors: a report from the Shanghai Breast Cancer Survival Study. Cancer Causes Control. 2013; 24:1747–1756. PMID: 23860950.

38. Grote S, Almstedt HC, Tarleton HP. Cardiometabolic Health Among Cancer Survivors: A 13-week pilot study of a combined aerobic and resistance training program. Oncol Nurs Forum. 2016; 43:306–315. PMID: 27105192.

39. Tonorezos ES, Robien K, Eshelman-Kent D, Moskowitz CS, Church TS, Ross R, et al. Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia. Cancer Causes Control. 2013; 24:313–321. PMID: 23187859.

40. Smith WA, Li C, Nottage KA, Mulrooney DA, Armstrong GT, Lanctot JQ, et al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer. 2014; 120:2742–2750. PMID: 25070001.

41. Cohen JE, Wakefield CE, Cohn RJ. Nutritional interventions for survivors of childhood cancer. Cochrane Database Syst Rev. 2016; (8):CD009678. PMID: 27545902.

42. Follin C, Thilén U, Ahrén B, Erfurth EM. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2006; 91:1872–1875. PMID: 16522695.

43. Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, Erfurth EM, Beck-Peccoz P, et al. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol. 2013; 168:565–573. PMID: 23359434.